Identification and genetic validation of leukemia inhibitory factor super‐enhancers in acute respiratory distress syndrome and lung cancer

Abstract

AbstractSuper‐enhancers play prominent roles in driving robust pathological gene expression, but they are hidden in human genome at noncoding regions, making them difficult to explore. Leukemia inhibitory factor (LIF) is a multifunctional cytokine crucially involved in acute respiratory distress syndrome (ARDS) and lung cancer progression. However, the mechanisms governing LIF regulation in disease contexts remain largely unexplored. In this study, we observed elevated levels of LIF in the bronchoalveolar lavage fluid (BALF) of patients with sepsis‐related ARDS compared to those with nonsepsis‐related ARDS. Furthermore, both basal and LPS‐induced LIF expression were under the control of super‐enhancers. Through analysis of H3K27Ac ChIP‐seq data, we pinpointed three potential super‐enhancers (LIF‐SE1, LIF‐SE2, and LIF‐SE3) located proximal to the LIF gene in cells. Notably, genetic deletion of any of these three super‐enhancers using CRISPR‐Cas9 technology led to a significant reduction in LIF expression. Moreover, in cells lacking these super‐enhancers, both cell growth and invasion capabilities were substantially impaired. Our findings highlight the critical role of three specific super‐enhancers in regulating LIF expression and offer new insights into the transcriptional regulation of LIF in ARDS and lung cancer.